JAK inhibitors provide a relatively tolerable drug option for controlling symptoms, reducing splenomegaly, and improving quality of life, but often at the expense of worsening cytopenias and without halting disease progression or preventing leukemic transformation. In this article, the authors review FDA–approved JAK inhibitors as well as those in late-phase clinical trials, and provide a schema for choosing among the available options for patients with MF.

Gilteritinib is standard therapy for relapsed/refractory FLT3-mutated (FLT3mut) AML but seldom reduces FLT3mut burden or induces sustained efficacy. This phase Ib open-label, dose-escalation/dose-expansion study enrolled 61 patients (63% having received prior FLT3 therapy) to receive 400 mg oral venetoclax once daily and 80 mg or 120 mg oral gilteritinib once daily. The combination of venetoclax and gilteritinib was associated with high mCRc and FLT3 molecular response rates regardless of prior FLT3 inhibitor exposure, but did require dose interruptions for myelosuppression.

Memorial Sloan Kettering oncologist Raajit Rampal presents a case report, discusses the rationale for the few treatment options available, and summarizes the 5-year follow-up data for the RESPONSE and RESPONSE 2 trials.

Here’s everything you could possibly want to know about “magic” mushrooms, including their short- and long-term effects on people, risks, history, and much more.

1.0 AMA PRA Category 1 Credit™1.0 ACPE contact hour (0.1 CEU) Release Date: May 1, 2022Expiration Date: May 1, 2023 Learning ObjectivesAfter completing this activity, participants should be better able to: Describe the pharmacologic and safety differences between conventional and atypical opioids. Recognize appropriate patients who might benefit from buprenorphine as a first-line opioid analgesic. Understand how to transition opioid therapy from full µ-opioid analgesics to buprenorphine when appropriate.

The greatest method to guarantee the best possible patient care, according to leaders of specialty pharmacies housed in health systems, is to supply specialized pharmaceuticals through the framework of a health system. It may be debatable which paradigm—the conventional standalone specialty pharmacies or the integrated model of health systems—is the best. However, it cannot be denied that a growing proportion of medications on the market are being introduced as specialty drugs.